In:
Die Kardiologie, Springer Science and Business Media LLC, Vol. 16, No. 6 ( 2022-12), p. 466-478
Abstract:
According to the new European Society of Cardiology (ESC) guidelines on the diagnostics and treatment of acute and chronic heart failure, vericiguat (Verquvo®) can be included in the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction who, despite standard treatment after a recently occurring decompensation event, were stabilized with the necessary intravenous (i.v.) therapy. Objective This review article summarizes the development of vericiguat, a soluble guanylate cyclase stimulator (sGC stimulator), which is a good example for the stringent implementation of a novel pharmacological therapy approach into treatment of heart failure. It provides valuable approaches for the practical use via the characterization of this patient collective that was investigated for the first time. Results The two relevant trials in the clinical development program for vericiguat, SOCRATES-Reduced and VICTORIA, have clearly demonstrated the efficacy and safety of vericiguat. The primary efficacy endpoint in the VICTORIA study “cardiovascular death or hospitalization due to heart failure” was significantly reduced in the vericiguat arm compared to placebo. Relevant subgroup analyses as well as safety data confirm this result and support the safe use in this high-risk population. Conclusion The presented data allow the conclusion that vericiguat can be efficaciously and safely added to an existing treatment with a recommended standard medication for heart failure. It can be expected that in the routine practice the target dose of 10 mg can be reliably reached and maintained. Vericiguat should be regarded as a novel, easy and safe treatment option in a vulnerable patient population, for which there was previously hardly any medicinal treatment option.
Type of Medium:
Online Resource
ISSN:
2731-7129
,
2731-7137
DOI:
10.1007/s12181-022-00576-y
Language:
German
Publisher:
Springer Science and Business Media LLC
Publication Date:
2022
detail.hit.zdb_id:
3120903-8
